Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Co-Packaged HIV Drug User Fees Likely To Be Waived By AIDS Relief Plan

Executive Summary

Most fixed-dose combination and co-packaged versions of previously approved antiretroviral HIV therapies are unlikely to require user fees under the President's $15 bil. Emergency Plan for AIDS Relief, according to a 1draft guidance released April 15

You may also be interested in...



FDA Collection Of 505(b)(2) User Fees Misguided – WLF Paper

FDA should only assess user fees on 505(b)(2) applications that make changes to the Indications & Usage section of labeling, according to a recent backgrounder from the Washington Legal Foundation

FDA Collection Of 505(b)(2) User Fees Misguided – WLF Paper

FDA should only assess user fees on 505(b)(2) applications that make changes to the Indications & Usage section of labeling, according to a recent backgrounder from the Washington Legal Foundation

AIDS Drug Combos Still Moving Slowly After FDA Guidance

GlaxoSmithKline and Boehringer Ingelheim are in discussions with FDA on a Combivir/Viramune co-package submission after signing a "letter of intent" to develop the product

Related Content

Topics

UsernamePublicRestriction

Register

PS045700

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel